Bristol Myers Squibb and Vertex Pharmaceuticals present investors with a clear choice: steady value versus high growth. The figure that matters? Vertex’s 32.7% net margin in FY 2025, nearly double Bristol Myers’ 14.6%.
Financial Performance: Revenue and Profitability
In FY 2025, Bristol Myers Squibb generated $48.2 billion in revenue, a slight 0.2% decline year-over-year. Vertex, meanwhile, saw revenue grow 9.6% to $12.1 billion. The bottom line? Vertex’s net income of $4.0 billion on a smaller revenue base highlights its efficiency, compared to Bristol Myers’ $7.1 billion.
Balance Sheet Health: Debt and Liquidity
By the numbers, Vertex’s debt-to-equity ratio of 0.2x signals a conservative financial stance, while Bristol Myers’ 2.6x ratio indicates higher leverage. Vertex’s current ratio of 2.9x also suggests stronger liquidity than Bristol Myers’ 1.3x.
Growth Prospects and Pipeline Risks
Vertex’s focus on cystic fibrosis and sickle cell disease has driven its growth, with treatments like Alyftrek expanding market reach. Bristol Myers, however, faces revenue concentration risks tied to key products like Eliquis and Opdivo, vulnerable to patent expirations and generic competition.
Valuation and Investment Strategy
Bristol Myers appears cheaper based on earnings multiples, reflecting its challenges. Vertex carries a higher valuation, justified by its growth and margins. Investors will note: Vertex’s strong pipeline and market position make it the pricier but more dynamic choice.
The figure that matters for investors? Vertex’s ability to maintain high margins and growth despite concentration risks. Talk to your financial advisor to determine which strategy aligns with your goals.
Sources
- Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027? | The Motley Fool
- Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027? | The Motley Fool
Photo: Coolcaesar at English Wikipedia (CC BY-SA 3.0)
